Aarhus Universitets segl

The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisKonferenceabstrakt i tidsskriftForskningpeer review

  • Søren Dinesen Østergaard
  • Leslie Foldager
  • Ole Mors
  • Per Beck, Psychiatric Research Unit, Mental Health Centre North Zealand, Copenhagen University Hospital, Hillerød, Denmark., Danmark
  • Christoph U Correll, The Zucker Hillside Hospital, Northwell Health, USA
A six-item version (PANSS-6: P1=Delusions, P2=Conceptual disorganization, P3=Hallucinations, N1=Blunted Affect, N4=Social withdrawal, N6=Lack of spontaneity/flow of conversation) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) has shown promise in the measurement of symptom severity in acutely exacerbated- and chronic schizophrenia, but its validity in treatment-resistant schizophrenia remains unknown. Therefore, we tested the validity and sensitivity of PANSS-6 based on data from the clozapine phase of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.

MethodsI) The scalability of PANSS-6 and PANSS-30 (i.e., whether all items provide unique information regarding syndrome severity) was tested by means of item response theory analysis ad modum Rasch; II) The correlation between PANSS-6 and PANSS-30 total scores was investigated by means of Spearman correlation analysis; III) The accuracy of PANSS-6 in identifying symptom remission was tested by comparing remission on PANSS-6 (score of ≤3 on each of the six PANSS-6 items) with remission according to the Andreasen criteria (score of ≤3 on the 8 PANSS items considered in the Andreasen criteria); and IV) The antipsychotic effect of clozapine was compared to that of olanzapine, risperidone and quetiapine using the “speed of change” on PANSS-6 and PANSS-30 (change in total score per day) as outcomes.

ResultsWe found that I) only PANSS-6 and not PANSS-30 was scalable; II) The correlation between PANSS-6 and PANSS-30 total scores was high (Spearman coefficient: 0.85), III) PANSS-6 did accurately classify syndrome remission as defined by the Andreasen criteria, and IV) The only antipsychotic that resulted in improvement (speed of change significantly lower than 0 during the first three months of treatment) was clozapine, both when using PANSS-6 (speed of change: -0.072 points/day; 95%CI: -0.121, -0.024) and when using PANSS-30 (speed of change: -0.201 points/day; 95%CI: -0.400, -0.002) as outcome measures.

DiscussionThese findings suggest that PANSS-6 validly measures severity, remission and antipsychotic efficacy in treatment-resistant schizophrenia.
TidsskriftSchizophrenia Bulletin
Sider (fra-til)S341-S342
StatusUdgivet - 1 apr. 2018
Begivenhed6th Biennial Conference of the Schizophrenia-International-Research-Society (SIRS) - Florence, Italien
Varighed: 4 apr. 20188 apr. 2018


Konference6th Biennial Conference of the Schizophrenia-International-Research-Society (SIRS)

Se relationer på Aarhus Universitet Citationsformater

ID: 143302503